Supplementary Materials

Supplementary Material for:

Normalization of CD4+ T cell metabolism reverses lupus

Yiming Yin, Seung-Chul Choi, Zhiwei Xu, Daniel J. Perry, Howard Seay, Byron P. Croker, Eric S. Sobel, Todd M. Brusko, Laurence Morel*

*Corresponding author. E-mail: morel{at}ufl.edu

Published 11 February 2015, Sci. Transl. Med. 7, 274ra18 (2015)
DOI: 10.1126/scitranslmed.aaa0835

This PDF file includes:

  • Fig. S1. TC mice showed enhanced CD4+ T cell activation.
  • Fig. S2. Representative FACS plots of ex vivo CD4+-gated T cells from B6 (black) and TC (red) mice for pS6, p4E-PB1, CD98, and CD71.
  • Fig. S3. CD4+ T cells from TC mice showed an altered expression of metabolic genes.
  • Fig. S4. IL-2 gating in CD4+ T cells.
  • Fig. S5. The Met + 2DG treatment normalized the metabolism of effector CD4+ T cells.
  • Fig. S6. A 3-month Met + 2DG in vivo treatment resulted in a global normalization of TC CD4+ T cell effector phenotypes.
  • Fig. S7. The Met + 2DG treatment did not have adverse effects on body weight and blood sugar.
  • Fig. S8. Met + 2DG treatment did not affect normal humoral response.
  • Fig. S9. One-month Met + 2DG treatment reduced disease severity in TC mice.
  • Fig. S10. Met + 2DG treatment prevented autoantibody production in the cGVHD model.
  • Fig. S11. 2DG treatment failed to reverse immunophenotypes in TC mice.
  • Fig. S12. Met treatment failed to reverse immunophenotypes in TC mice.
  • Fig. S13. CD4+ T cell immunophenotypes in SLE patients.
  • Table S1. Human subject demographics and disease parameters.
  • Table S2. Primers for qPCR assays.
  • Table S3. Antibodies used in this study.
  • Legend for table S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S4. Source data (Excel file).

[Download Table S4]